Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Filings indexed 1,159 across all filing types
Latest filing 2016-03-08 Capital/Financing Update
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Extension of SPP Closing Date to 29 March 2016 2 pages 232.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited regarding the extension of the closing date for a Share Purchase Plan (SPP). It provides details about the revised timetable for the SPP offer period and instructions for shareholders. There is no financial report, earnings data, or detailed financial analysis included. The document is a specific update on a capital raising activity (SPP), which falls under financing activities. Therefore, the document is best classified as a Capital/Financing Update (CAP). The document length is about 5,196 characters, which is sufficient for a detailed announcement but does not constitute a full financial report or other types of filings.
2016-03-08 English
Half Yearly Report and Accounts 23 pages 801.1KB
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "Half yearly report ended 31 December 2015" and contains detailed financial information including consolidated operating loss, net assets, cash flow, and a directors' report. It includes comprehensive financial statements such as the statement of profit or loss, statement of financial position, cash flows, notes, and auditor's review report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content and structure clearly indicate it is a comprehensive interim financial report covering a six-month period, which fits the definition of an Interim / Quarterly Report (IR). H1 2016
2016-02-25 English
Dispatch of Share Purchase Plan Offer Documents 11 pages 601.9KB
Capital/Financing Update Classification · 95% confidence The document is a detailed communication from Living Cell Technologies Limited regarding a Share Purchase Plan (SPP) offer to shareholders. It includes the offer terms, application form, timetable, eligibility criteria, and instructions for payment. The content focuses on raising capital through a share purchase plan, which is a financing activity. There are no financial statements or earnings data presented, so it is not an earnings release or financial report. The document is not a proxy statement, AGM material, or management report. It is a capital raising announcement with detailed offer documentation. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is the actual offer document, not just an announcement of a report.
2016-02-22 English
Becoming a substantial holder 2 pages 155.9KB
Regulatory Filings Classification · 100% confidence The document text contains only placeholders for omitted pictures and no substantive text content. The true document length is only 232 characters, which is extremely short and contains no financial data, report content, or announcements. It does not contain any report, announcement, or certification text. Given the lack of content and the presence of only images (omitted), this document cannot be classified as a report or announcement. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2016-02-18 English
Appendix 3B 9 pages 199.8KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX listing rules (Rule 2.7, 3.10.3, etc.). It details the issuance of new ordinary shares, including number of shares, issue price, purpose of the issue, and quotation application for additional securities. The content is consistent with a formal announcement of a new share issue and application for quotation on the ASX. There are no financial statements or management discussion, nor is this a report or presentation. The document is a regulatory announcement about capital raising and share issuance. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP).
2016-02-17 English
Cleansing Statement 1 page 195.9KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A of the Corporations Act regarding the issuance of shares by Living Cell Technologies Limited. It details a share placement and compliance with disclosure requirements but does not contain financial statements or detailed financial data. The document is short (1142 characters) and serves as a regulatory announcement about a capital raising event. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2016-02-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.